A double - blind , randomized , controlled , multicenter study to <font color="blue">assess_1</font> <font color="blue">the_1</font> <font color="blue">safety_2</font> <font color="blue">and_2</font> <font color="blue">cardiovascular_2</font> <font color="blue">effects_2</font> of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction . 
<br>
<br> BACKGROUND We sought to <font color="blue">determine_1</font> <font color="blue">the_1</font> <font color="blue">safety_2</font> <font color="blue">and_2</font> <font color="blue">preliminary_2</font> <font color="blue">efficacy_2</font> of transcatheter intramyocardial administration of myoblasts in patients with heart failure ( HF ) . 
<br> METHODS MARVEL is a randomized placebo - controlled trial of image - guided , catheter - based intramyocardial injection of placebo or myoblasts ( 400 or 800 million ) in patients with class II to IV HF and ejection fraction < 35% . Primary end points were <font color="blue">frequency_2</font> <font color="blue">of_2</font> <font color="blue">serious_2</font> <font color="blue">adverse_3</font> <font color="blue">events_3</font> <font color="blue">(_3</font> <font color="blue">safety_3</font> <font color="blue">)_3</font> <font color="blue">and_1</font> <font color="blue">changes_2</font> <font color="blue">in_2</font> <font color="blue">6-minute_2</font> <font color="blue">walk_2</font> <font color="blue">test_2</font> <font color="blue">and_1</font> <font color="blue">Minnesota_3</font> <font color="blue">Living_3</font> <font color="blue">With_3</font> <font color="blue">HF_3</font> <font color="blue">score_3</font> <font color="blue">(_3</font> <font color="blue">efficacy_3</font> <font color="blue">)_3</font> <font color="blue">._3</font> Of 330 patients intended for enrollment , 23 were randomized ( MARVEL-1 ) before stopping the study for financial reasons . 
<br> RESULTS At 6 months , similar <font color="blue">numbers_1</font> <font color="blue">of_1</font> <font color="blue">events_1</font> occurred in each group : 8 ( placebo ) , 7 ( low dose ) , and 8 ( high dose ) , without <font color="blue">deaths_1</font> <font color="blue">._1</font> <font color="blue">Ventricular_3</font> <font color="blue">tachycardia_3</font> <font color="blue">responsive_2</font> <font color="blue">to_2</font> <font color="blue">amiodarone_2</font> was <font color="blue">more_1</font> <font color="blue">frequent_1</font> in myoblast - treated patients : 1 ( placebo ) , 3 ( low dose ) , and 4 ( high dose ) . A trend toward <font color="blue">improvement_1</font> in <font color="blue">functional_3</font> <font color="blue">capacity_3</font> was noted in myoblast - treated groups ( Î”6-minute walk test of -3.6 vs + 95.6 vs + 85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) <font color="blue">without_1</font> <font color="blue">significant_1</font> <font color="blue">changes_1</font> in <font color="blue">Minnesota_1</font> <font color="blue">Living_1</font> <font color="blue">With_1</font> <font color="blue">HF_1</font> <font color="blue">scores_1</font> <font color="blue">._1</font> 
<br> CONCLUSIONS In HF patients with chronic postinfarction cardiomyopathy , transcatheter administration of myoblasts in doses of 400 to 800 million cells is feasible and may lead to important <font color="blue">clinical_1</font> <font color="blue">benefits_1</font> <font color="blue">._1</font> <font color="blue">Ventricular_2</font> <font color="blue">tachycardia_2</font> may be provoked by myoblast injection but appears to be a transient and treatable problem . A large - scale outcome trial of myoblast administration in HF patients with postinfarction cardiomyopathy is feasible and warranted .